Abstract
We report the final results of a prospectively randomized study that compared the combination of epirubicin, cisplatin and protracted venous infusion fluorouracil (5-FU) (ECF regimen) with the standard combination of 5-FU, doxorubicin and methotrexate (FAMTX) in previously untreated patients with advanced oesophagogastric cancer. Between 1992 and 1995, 274 patients with adenocarcinoma or undifferentiated carcinoma were randomized from eight oncology centres in the UK and analysed for response and survival. The overall response rate was 46% (95% confidence interval (CI), 37–55%) with ECF, and 21% (95% CI, 13–28%) with FAMTX (P = 0.00003). The median survival was 8.7 months with ECF and 6.1 months with FAMTX (P = 0.0005). The 2-year survival rates were 14% (95% CI, 8–20%) for the ECF arm, and 5% (95% CI, 2–10%) for the FAMTX arm (P = 0.03). Histologically complete surgical resection following chemotherapy was achieved in ten patients in the ECF arm (three pathological complete responses to chemotherapy) and three patients in the FAMTX arm (no pathological complete responses). The ECF regimen resulted in a response and survival advantage compared with FAMTX chemotherapy. The probability of long-term survival following surgical resection of residual disease is increased by this treatment. The high response rates seen with ECF support its use in the neoadjuvant setting.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Allum, W. H., Powell, D. J., McConkey, C. C. & Fielding, J. W. (1989) Gastric cancer: a 25-year review. Br J Surg 76: 535–540.
Beer, M., Cocconi, G., Ceci, G., Varini, M. & Cavalli, F. (1983) A phase II study of cisplatin in advanced gastric cancer. Eur J Cancer Clin Oncol 19: 717–720.
Cascinu, S., Labianca, R., Alessandroni, P., Marcellini, M., Silva, R. R., Pancera, G., Testa, E., Martignoni, G., Barni, S., Frontini, L., Zaniboni, A., Luporini, G., Cellerino, R. & Catalano, G. (1997) Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol 15: 3313–3319.
Cersosimo, R. J. & Hong, W. K. (1986) Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 4: 425–439.
Cocconi, G., Bella, M., Zironi, S., Algeri, R., Di Costanzo, F., De Lisi, V., Luppi, G., Mazzocchi, B., Rodino, C., Soldani, M., Gilli, G. & Finardi, C. (1994) Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 12: 2687–2693.
Cunningham, D., Mansi, J., Ford, H. T., Nash, A. T. & Menzies Gow, N. (1991) Epirubicin, Cisplatin and 5-Fluorouracil (ECF) Is Highly Effective In Advanced Gastric Cancer (Meeting Abstract). Proc Annu Meet Am Soc Clin Oncol 10: 136
Etienne, M. C., Bernard, S., Fischel, J. L., Formento, P., Gioanni, J., Santini, J., Demard, F., Schneider, M. & Milano, G. (1991) Dose reduction without loss of efficacy for 5-flourouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines. Br J Cancer 63: 372–377.
Findlay, M., Cunningham, D., Norman, A., Mansi, J., Nicolson, M., Hickish, T., Nicolson, V., Nash, A., Sacks, N., Ford, H., Carter, R. & Hill, A. (1994) A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5: 609–616.
Glimelius, B., Ekstrom, K., Hoffman, K., Graf, W., Sjoden, P. O., Haglund, U., Svensson, C., Enander, L. K., Linne, T., Sellstrom, H. & Heuman, R. (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8: 163–168.
Kelsen, D., Atiq, O. T., Saltz, L., Niedzwiecki, D., Ginn, D., Chapman, D., Heelan, R., Lightdale, C., Vinciguerra, V. & Brennan, M. (1992) FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 10: 541–548.
Lokich, J. J., Ahlgren, J. D., Gullo, J. J., Philips, J. A. & Fryer, J. G. (1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 7: 425–432.
Machover, D., Goldschmidt, E., Chollet, P., Metzger, G., Zittoun, J., Marquet, J., Vandenbulcke, J. M., Misset, J. L., Schwarzenberg, L., Fourtillan, J. B., Gaget, H. & Mathe, G. (1986) Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4: 685–696.
Melcher, A. A., Mort, D. & Maughan, T. S. (1996) Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer. Br J Cancer 74: 1651–1654.
Miller, A. B., Hoogstraten, B., Staquet, M. & Winkler, A. (1981) Reporting results of cancer treatment. Cancer 47: 207–214.
Murad, A. M., Santiago, F. F., Petroianu, A., Rocha, P. R., Rodrigues, M. A. & Rausch, M. (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72: 37–41.
Plukker, J. T., Mulder, N. H., Sleijfer, D. T., Grond, J. & Verschueren, R. C. J. (1991) Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil. Br J Surg 78: 955–958.
Plukker, J. T., Sleijfer, D. T., Verschueren, R. C. J., Van der Graaf, W. T. A. & Mulder, N. H. (1995) Neo-adjuvant chemotherapy with carboplatin, 4-epiadriamycin and teniposide (CET) in locally advanced cancer of the cardia and lower oesophagus: a phase II study. Anticancer Res 15: 2357–2362.
Preusser, P., Wilke, H., Achterrath, W., Fink, U., Lenaz, L., Heinicke, A., Meyer, J., Meyer, H. J. & Buente, H. (1989) Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7: 1310–1317.
Pyrhonen, S., Kuitunen, T., Nyandoto, P. & Kouri, M. (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71: 587–591.
Rougier, P., Mahjoubi, M., Lasser, P., Ducreux, M., Oliveira, J., Ychou, M., Pignon, J. P., Elias, D., Bellefqih, S., Bognel, C., Lusinchi, A., Cvitkovic, E. & Droz, J. P. (1994) Neoadjuvant chemotherapy in locally advanced gastric carcinoma – a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. Eur J Cancer 30A: 1269–1275.
Webb, A., Cunningham, D., Scarffe, J. H., Harper, P., Norman, A., Joffe, J. K., Hughes, M., Mansi, J., Findlay, M., Hill, A., Oates, J., Nicolson, M., Hickish, T., O’Brien, M., Iveson, T., Watson, M., Underhill, C., Wardley, A. & Meehan, M. (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15: 261–267.
Wilke, H., Preusser, P., Fink, U., Gunzer, U., Meyer, H. J., Meyer, J., Siewert, J. R., Achterrath, W., Lenaz, L., Knipp, H. & Schmoll, H. J. (1989) Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin and cisplatin. J Clin Oncol 7: 1318–1326.
Wilke, H., Wils, J., Rougier, P., Lacave, A., Van Cutsem, E., Vanhoeferi, U., Sahmoud, T., Curran, D. & Marinus, A. (1995) Preliminary analysis of a randomized phase III trial of FAMTX versus ELF versus cisplatin/FU in advanced gastric cancer. A trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group and the AIO (Arbeitsgemeinschaft Internistische Onkologie) (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 14: 206
Wils, J. A., Klein, H. O., Wagener, D. J., Bleiberg, H., Reis, H., Korsten, F., Conroy, T., Fickers, M., Leyvraz, S., Buyse, M. & Duez, N. (1991) Sequential high-dose methotrexate and fluorouracil combined with doxorubicin – a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 9: 827–831.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Waters, J., Norman, A., Cunningham, D. et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 80, 269–272 (1999). https://doi.org/10.1038/sj.bjc.6690350
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690350
Keywords
This article is cited by
-
Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review
Gastric Cancer (2018)
-
A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer
Cancer Chemotherapy and Pharmacology (2016)
-
Esophagogastric Adenocarcinoma: Is More Chemotherapy Better?
Current Treatment Options in Oncology (2016)
-
Histological complete response to a combined docetaxel/cisplatin/fluorouracil neoadjuvant chemotherapy for T4 stage gastric adenocarcinoma
World Journal of Surgical Oncology (2014)
-
Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort
Gastric Cancer (2014)
